TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR: A POTENTIAL THERAPEUTIC FOR ALZHEIMER’S DISEASE